Abstract
Background: 24% of all new breast cancers are diagnosed in patient’s aged over 75. The recent 2020 National Audit of Breast Cancer in the Older Population (NABCOP) report highlighted a large variation in the treatment offered geographically within the UK. The report recommended surgery should be offered where possible given its survival benefit over primary endocrine therapy (PET). However, this is not the case for many patients in the UK and the reasons why are not clear. An individual patient’s overall survival benefit can be calculated using the Age Gap Decision Tool which performs a multivariant analysis based on co-morbidities, tumour characteristics and a patient’s ability to undertake certain activities of daily living.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
